Spring Bank Pharmaceuticals, which is developing small molecule therapies for hepatitis B and viral diseases, raised $11 million by offering 0.9 million shares at $12, the low end of the range of $12 to $14. Spring Bank Pharmaceuticals plans to list on the Nasdaq under the symbol SBPH. Dawson James acted as a lead manager on the deal.
